A Phase 1 Study Evaluating High Dose ADXS11-001 Treatment in Women With Carcinoma of the Cervix (ADXS001-07)
Latest Information Update: 22 May 2024
At a glance
- Drugs Axalimogene filolisbac (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Advaxis
- 04 Mar 2019 Status changed from active, no longer recruiting to completed.
- 15 May 2017 According to an Advaxis media release, Sharad Ghamande from Georgia Cancer Center at Augusta University is the principal investigator of this trial.
- 27 Mar 2017 According to an Advaxis media release, one patient from this trial was featured in the Augusta Chronicle.